TSC2 and neoplasm: A total of 26 presumed germline pathogenic variants in 24 patients (14.3%) were nominated by a germline-focused tumor analysis in the following genes: SMAD4 (n = 6), BRCA2 (n = 4), PTEN (n = 3), BRCA1 (n = 3), RB1 (n = 2), STK11 (n = 2), ATM (n = 1), BRIP1 (n = 1), MSH6 (n = 1), RAD51 (n = 1), TP53 (n = 1), and TSC2 (n = 1) (Table 2).